Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. They are focused on developing new medicines to treat patients with respiratory diseases such as cystic fibrosis, asthma, and COPD, aiming to improve patient quality of life and reduce the frequency of lung infections.

Henry Danahay

Enterprise Therapeutics

Sonavi Labs develops advanced medical devices and software rooted in AI and applied to auscultation, aimed at detecting and managing respiratory diseases.

Sonavi Labs

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. 

The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Cystic Fibrosis Foundation

Cystic Fibrosis Trust

Imperial Innovations

IP Group

Epidarex Capital

Forbion Capital Partners

Novartis Venture Fund

Versant Ventures

#CysticFibrosis affects over 10,800 people in the UK, with one in 25 of us carrying the #gene #mutation that causes it, often without knowing.

Join us for #CFWeek to raise awareness and celebrate the #innovative progress that the #scientific community has already made in #CF #research, #drugdiscovery and #drugdevelopment, as well as the exciting breakthroughs on the horizon.

You can get involved with Cystic Fibrosis Trust here: https://rb.gy/li8ux 
#CysticFibrosisAwareness

What is the importance of endpoints in #raredisease #research?
 
In conversation with International Clinical Trials (Samedan Ltd), our CMO, Dr Niyati Prasad shares her insight on conducting #clinicaltrials for rare diseases, from how #researchers can best select primary and secondary endpoints to the role of ePROs.
 
Read the full interview here: https://bit.ly/3C6hZ0p

Every May, the #cysticfibrosis community comes together for #CFAwarenessMonth, with the unified aim to raise #disease awareness and find a cure for all people with #CF.

Joining this mission, Enterprise Therapeutics is dedicated to the #research, development, and delivery of novel muco-regulatory treatments for CF and other #respiratorydiseases. 

Learn more about our approach here: https://bit.ly/3o6E2An

Our Chief #Medical Officer, Dr Niyati Prasad, is presenting at #Clinical #Outsourcing Group UK.
 
Join Niyati to hear key insights on identifying accurate endpoints to improve clinical study design for #rarediseases.
 
Learn more and register here: https://bit.ly/3X0Wh6P #COGUK

Metric
Company Name	Enterprise Therapeutics	Sonavi Labs
Symbol
MSH ID	COM:ENTERPRISETHERAPEUTICS	COM:SONAVILABS
Market	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Medical Devices
Country	GB	US
Stage	Series B	Non Equity Assistance
Employee Count	13
Website	enterprisetherapeutics.com	sonavilabs.com
LinkedIn	enterprise-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	856
Web Traffic Growth	-0.54
Valuation
Raised Capital	33.06M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ENTERPRISETHERAPEUTICS

Enterprise Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue